Nintedanib - Boehringer Ingelheim

Drug Profile

Nintedanib - Boehringer Ingelheim

Alternative Names: BIBF-1120; Intedanib; Ofev; Vargatef

Latest Information Update: 01 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Carolinas HealthCare System; European Organisation for Research and Treatment of Cancer; M. D. Anderson Cancer Center; Roswell Park Cancer Institute; University of Alabama at Birmingham; University of Texas Southwestern Medical Center
  • Class Acetamides; Antifibrotics; Antineoplastics; Esters; Indoles; Piperazines; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Protein tyrosine kinase inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Interstitial lung diseases; Systemic scleroderma; Idiopathic pulmonary fibrosis; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic pulmonary fibrosis; Non-small cell lung cancer
  • Phase III Colorectal cancer; Interstitial lung diseases; Mesothelioma; Ovarian cancer; Systemic scleroderma
  • Phase II Bladder cancer; Endometrial cancer; Gastrointestinal cancer; Inflammatory breast cancer; Liver cancer; Renal cell carcinoma; Soft tissue sarcoma
  • Phase I/II Pancreatic cancer
  • Phase I Solid tumours
  • No development reported Fallopian tube cancer; Multiple myeloma; Peritoneal cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 25 Sep 2018 Efficacy and adverse events data from the phase III LUME-Meso trial in Mesothelioma released by Boehringer Ingelheim
  • 25 Sep 2018 Boehringer Ingelheim terminates the phase III LUME-Meso trial in Mesothelioma in USA, Australia, Europe, Canada, Egypt, Israel, Japan, South Africa, Turkey, Argentina, Chile, Mexico and Russia due to negative results (failure to meet primary endpoint) (NCT01907100)
  • 18 Sep 2018 Updated efficacy data from a phase III INPULSIS-ON trial in idiopathic pulmonary fibrosis released by Boehringer Ingelheim
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top